An improved understanding of the mechanistic link between chronically elevated FGF23 and LV hypertrophy or other untoward cardiovascular side effects such as hypertension is of major importance, not only for XLH patients but for all diseases characterized by chronic elevations of circulating intact FGF23, such as CKD. Here, FGF23 is linked to X-linked hypophosphatemia.